Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis.
Lycera Closes $36 Million Series A
Lycera announced the closing of a $36M Series A round of funding. The company is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, has ...
Synageva Nets $30M
Synageva BioPharma announced the first closing of a financing raising $30 million. The round was led by Baker Brothers Investments. Other investors participating in the financing include Tullis Dickerson and Four Partners. ...
Shorting Dendreon
In retrospect... not a good idea. Already up 189% today presumably after the short squeeze.
Layoffs and Such
I promise... they posting will return next week. Due to the recent layoff at my company, I'm going to have plenty of time to make up for the last few weeks.
AVEO and Biogen Team Up
AVEO and Biogen announced a strategic collaboration for the development and commercialization of AVEO’s novel discovery-stage ErbB3-targeted antibodies for the potential treatment of cancer and other diseases. TERMS ------------------------- - AVEO will receive upfront and ...
CV Tells Astellas to Shove It: Looks to Gilead
All this talk by Astellas about taking over the board of directors and taking the decisision to the shareholders seems it may have been in vain. Gilead has agreed to acquire ...
Mega-mergers Are Not Good For Business
There's an article this morning on Bloomberg insinuating that the Pfizer/Wyeth, Genentech/Roche and now Merck/Schering-Plough mergers have placed pressure on the remaining members of big pharma to get into the game. ...
Merck to Buy Schering-Plough for $41.1 Billion Cash and Stock Deal
Not to be outdone by Pfizer / Wyeth, Merck and Schering-Plough announced that their Boards of Directors have unanimously approved a merger. Schering has a strong pipeline and was my best ...
Symphogen and Origen Collaborate Will Develop Transgenic Chickens Capable Of…..
[caption id="" align="alignleft" width="200" caption="From hddod onFlickr"][/caption] Sounds ominous, no? Symphogen and Origen announced a collaboration to develop a transgenic chicken capable of producing human antibodies against a wide variety of disease targets. ...
Proteon Therapeutics Has A Big Day
Proteon Therapeutics announced it has successfully completed a $38 million Series B equity financing, started a Phase 1/2 clinical trial with its lead product, PRT-201, and has entered into an option agreement ...
Vertex to Buy Hepatitis C Drug Developer ViroChem for $375M
Vertex, which is developing the hepatitis C virus (HCV) protease inhibitor telaprevir, will add two polymerase inhibitors to its HCV drug development portfolio through an agreement to acquire privately-held ViroChem Pharma in ...
They Weren’t Bluffing: Astellas Lauches Tender Offer for CV Therapeutics
Astellas announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all outstanding shares of common stock of CV Therapeutics at a price of US$16.00 per share. ...
Heptares Secures $30M in Series A Funding
Heptares Therapeutics, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), annnouced it has raised $30M (GBP21M) of equity finance in a successful Series A private round from three blue-chip ...
Lilly Taps NeuroSearch For Preclinical Discovery Deal
Just a week after NeuroSearch failed a phase II pain trial (ABT-894), they've inked a collaboration which will focus on new CNS therapeutics based upon defined ion channel targets ...
Orexo Licenses Development for OX17 to Mystery Suitor
Orexo has signed an exclusive development agreement with "a large healthcare company", providing for joint development within Orexo’s OX17 program for gastroesophageal reflux disease (GERD), and will be discontinuing all other licensing ...